Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Key Insights

During the forecast period 2023-2033, the global market for prostate treatments for benign prostatic hyperplasia (BPH). is expected to reach an estimated value of ~USD 13.0 billion by 2033 by expanding at a CAGR of ~6%. The market generated ~$7.0 billion in additional revenue in 2022. Major key factors driving the growth of the global benign prostatic hyperplasia (BPH) prostate treatment market worldwide are higher demand for the treatment for the surgical treatment of BPH due to the severity of the condition. As of 2018, about 11,000 out of every 100,000 people received surgical treatment for benign prostatic hyperplasia.

Get a sample copy of the [email protected] https://www.researchnester.com/sample-request-4218

market definition of Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market.

Benign prostatic hyperplasia is a condition in which the size of the prostate decreases in men as they age. Benign prostatic hyperplasia is a condition that blocks the flow of urine and semen due to the size of the prostate glands. Therefore, it can be very uncomfortable for the affected person and people are very reluctant to talk about this disease. This disease can negatively affect the physical and mental health of the person. Therefore, the higher treatment demand is expected to boost the market growth over the forecast period.

Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment: growth accelerator

The growth of the global benign prostatic hyperplasia (BPH) prostate treatment market can be mainly attributed to the skyrocketing research and development process to find new systems and drugs to cure the disease. For example, one system, Rezum System, introduced by NxThera, Inc. has been observed to be more effective and faster in results compared to other pharmaceuticals for benign prostatic hyperplasia. On the other hand, market growth can also…